RESUMEN
Varicella-zoster virus infections have increased globally, with complications such as postherpetic neuralgia and neurological sequelae. The recombinant vaccine against herpes zoster is proposed as a preventive strategy. This systematic review evaluates its effectiveness and safety in healthy and high-risk populations. A systematic review of randomized controlled trials comparing the effectiveness and safety of the vaccine was conducted. The search was carried out in Epistemonikos. Two researchers independently assessed the eligibility of the studies and the risk of bias was evaluated using the Cochrane Risk of Bias 2 tool. A meta-analysis of homogeneous results was conducted, and the certainty of the evidence was evaluated using GRADE. A minimally contextualized approach was adopted using predetermined thresholds. Nine randomized controlled trials were selected. The vaccine demonstrated a significant reduction in the incidence of herpes zoster in high-risk populations (risk difference of 140 fewer per 1000) with high certainty. However, in healthy populations, the effect was trivial (28 fewer per 1000). No significant differences were observed in postherpetic neuralgia in any of the populations analyzed. Adverse events increased in both populations, though no discrepancies in serious adverse events were noted. In high-risk populations, where the incidence of herpes zoster and its complications is higher, the vaccine demonstrated effectiveness in lowering the incidence of the disease, though not in that of postherpetic neuralgia. Conversely, in healthy populations, the impact of the vaccine was trivial. Individualized and informed recommendations are crucial when considering this vaccine.
Las infecciones por el virus de la varicela-zóster han aumentado globalmente, con complicaciones como neuralgia postherpética y secuelas neurológicas. La vacuna recombinante contra el herpes zóster se propone como estrategia preventiva. Esta revisión sistemática evalúa su efectividad y seguridad en poblaciones sanas y de alto riesgo. Se realizó una revisión sistemática de ensayos controlados aleatorios que comparaban la efectividad y seguridad de la vacuna. La búsqueda se efectuó en Epistemonikos. Dos investigadores evaluaron independientemente la elegibilidad de los estudios y se evaluó el riesgo de sesgo con la herramienta Cochrane Risk of Bias 2. Se realizó un metanálisis de resultados homogéneos y se evaluó la certeza de la evidencia mediante GRADE. Se adoptó un enfoque mínimamente contextualizado utilizando umbrales predeterminados. Se seleccionaron 9 ensayos controlados aleatorios. La vacuna demostró una reducción significativa en la incidencia de herpes zóster en poblaciones de alto riesgo (diferencia de riesgo de 140 menos por 1000) con alta certeza. Sin embargo, en poblaciones sanas, el efecto fue trivial (28 menos por 1000). No se observaron diferencias significativas en la incidencia de neuralgia postherpética en ninguna de las poblaciones. En cuanto a la seguridad, se registró un aumento de eventos adversos en ambas poblaciones, aunque no se presentaron diferencias en los eventos adversos graves. En poblaciones de alto riesgo, donde la incidencia de herpes zóster y sus complicaciones es más alta, la vacuna demostró eficacia en la reducción de la incidencia de la enfermedad, aunque no en la de la neuralgia postherpética. Por otro lado, en población sana, el impacto de la vacuna fue trivial. Es crucial adoptar un enfoque individualizado e informado al recomendar esta vacuna.
Asunto(s)
Vacuna contra el Herpes Zóster , Herpes Zóster , Eficacia de las Vacunas , Humanos , Herpes Zóster/complicaciones , Herpes Zóster/epidemiología , Herpes Zóster/prevención & control , Vacuna contra el Herpes Zóster/efectos adversos , Vacuna contra el Herpes Zóster/administración & dosificación , Incidencia , Neuralgia Posherpética/epidemiología , Neuralgia Posherpética/prevención & control , Ensayos Clínicos Controlados Aleatorios como Asunto , Eficacia de las Vacunas/estadística & datos numéricos , Vacunas Sintéticas/administración & dosificación , Vacunas Sintéticas/efectos adversosRESUMEN
Under two detection schemes, this study analyzes one of the most destructive weather systems - the explosive cyclones - in the South Atlantic, from 2010 to 2020. Then, two methods are presented to study these systems: the Observational Method (OBSM) and the Automated Method (AUTM). The first uses visual analysis of the mean sea level pressure (mslp) fields and functions to identify the local minimums using the Grid Analysis and Display (GrADS) software. The second utilizes a function from OpenGrADS called mfhilo. It shows the local minimum in the grid using laplacian, magnitude, and percentile. Two shell algorithms for data manipulation are used for the AUTM: one to trace the cyclones' trajectories according to a previously defined fixed area and the other to separate them into explosives. The OBSM methodology showed 271 cases averaging 25 yearly and revealed important characteristics regarding the intensities. According to AUTM's methodology, from the 2705 ordinary cyclone cases identified, 299 are explosives. There is a clear seasonality pattern in the systems' distribution along South America, similar to OBSM, but more highlighted. In summer, they concentrate at high latitudes, while in winter and spring, they are assembled near southern Brazilian and Uruguayan coasts.
Asunto(s)
Tormentas Ciclónicas , Estaciones del Año , Brasil , Océano Atlántico , Algoritmos , Monitoreo del Ambiente/métodos , Sustancias Explosivas/análisisRESUMEN
Resumen En Argentina, el virus del dengue ha experimentado un aumento en los últimos años. Este estudio se propone realizar una revisión sistemática para evaluar la efec tividad y seguridad de la vacuna TAK-003 tetravalente contra el dengue en este contexto. Se llevó a cabo una revisión sistemática de ensayos clínicos controlados aleatorizados que comparaban la efectividad y seguridad de la vacuna con placebo en la población general. La búsqueda se efectuó en Episte monikos y dos investigadores evaluaron los estudios de manera independiente. El riesgo de sesgo se evaluó con la herramienta Rob 2 de Cochrane. Se realizó un metaa nálisis de los resultados y la certeza en la evidencia se evaluó mediante la metodología GRADE. Concluimos, con alta certeza de evidencia, que la vacuna tetravalente contra el dengue reduce las infec ciones graves (RR 0.17, IC 95% 0.12 a 0.24) e infecciones por el virus del dengue (RR 0.40, IC 95% 0.36 a 0.45) en una población de ≤17 años. La vacuna podría no incre mentar el riesgo de eventos adversos serios, aunque es importante destacar la baja certeza de evidencia (RR 1.04, IC 95%: 0.69-1.55). La aplicación de la vacuna tetravalente contra el dengue disminuye el riesgo de infecciones graves y no graves por el dengue en esa población. No obstante, existe baja certeza en la evidencia en relación a la se guridad de la vacuna. La decisión de la vacunación debe considerar la magnitud de los beneficios en función del riesgo de infección.
Abstract In Argentina, the dengue virus has experienced an increase in recent years. This study aims to conduct a systematic review to assess the effectiveness and safety of the tetravalent dengue vaccine TAK-003 in this context. A systematic review of randomized controlled clini cal trials comparing the effectiveness and safety of the vaccine with a placebo in the general population was conducted. The search was carried out on Epistemoni kos, and two investigators independently evaluated the studies. Bias risk was assessed using Cochrane's Rob 2 tool. A meta-analysis of the results was performed, and the certainty of evidence was evaluated using the GRADE methodology. We concluded, with high certainty of evidence, that the tetravalent dengue vaccine reduces severe infections (RR 0.17, 95% CI 0.12 to 0.24) and infections by the den gue virus (RR 0.40, 95% CI 0.36 to 0.45) in a population aged ≤17 years. The vaccine may not increase the risk of serious adverse events, although it is important to note the low certainty of evidence (RR 1.04, 95% CI: 0.69-1.55). The use of the tetravalent dengue vaccine decreases the risk of severe and non-severe dengue infections in this population. However, there is low certainty of evidence regarding the vaccine's safety. The decision to vaccinate should consider the magnitude of benefits relative to the risk of infection.
RESUMEN
In Argentina, the dengue virus has experienced an increase in recent years. This study aims to conduct a systematic review to evaluate the effectiveness and safety of the TAK-003 tetravalent dengue vaccine in this context. A systematic review of randomized controlled trials comparing the effectiveness and safety of the vaccine with placebo in the general population was conducted. The search was carried out in Epistemonikos, and two researchers independently assessed the studies. Risk of bias was evaluated using the Cochrane Rob 2 tool. A meta-analysis of the results was performed, and the certainty of evidence was assessed using the GRADE methodology. We concluded, with high certainty of evidence, that the tetravalent dengue vaccine reduces severe infections (RR 0.17, 95% CI 0.12 to 0.24) and infections by the dengue virus (RR 0.40, 95% CI 0.36 to 0.45) in a population ≤17 years. The vaccine may not increase the risk of serious adverse events, although it is important to note the low certainty of evidence (RR 1.04, 95% CI: 0.69-1.55). The use of the tetravalent dengue vaccine decreases the risk of severe and non-severe dengue infections in this population. However, there is low certainty of evidence regarding the vaccine's safety. The decision to vaccinate should consider the magnitude of benefits relative to the risk of infection.
En Argentina, el virus del dengue ha experimentado un aumento en los últimos años. Este estudio se propone realizar una revisión sistemática para evaluar la efectividad y seguridad de la vacuna TAK-003 tetravalente contra el dengue en este contexto. Se llevó a cabo una revisión sistemática de ensayos clínicos controlados aleatorizados que comparaban la efectividad y seguridad de la vacuna con placebo en la población general. La búsqueda se efectuó en Epistemonikos y dos investigadores evaluaron los estudios de manera independiente. El riesgo de sesgo se evaluó con la herramienta Rob 2 de Cochrane. Se realizó un metaanálisis de los resultados y la certeza en la evidencia se evaluó mediante la metodología GRADE. Concluimos, con alta certeza de evidencia, que la vacuna tetravalente contra el dengue reduce las infecciones graves (RR 0.17, IC 95% 0.12 a 0.24) e infecciones por el virus del dengue (RR 0.40, IC 95% 0.36 a 0.45) en una población de ≤17 años. La vacuna podría no incrementar el riesgo de eventos adversos serios, aunque es importante destacar la baja certeza de evidencia (RR 1.04, IC 95%: 0.69-1.55). La aplicación de la vacuna tetravalente contra el dengue disminuye el riesgo de infecciones graves y no graves por el dengue en esta población. No obstante, existe baja certeza en la evidencia en relación a la seguridad de la vacuna. La decisión de la vacunación debe considerar la magnitud de los beneficios en función del riesgo de infección.
Asunto(s)
Vacunas contra el Dengue , Dengue , Humanos , Vacunas contra el Dengue/efectos adversos , Vacunas contra el Dengue/administración & dosificación , Vacunas contra el Dengue/inmunología , Dengue/prevención & control , Ensayos Clínicos Controlados Aleatorios como Asunto , Eficacia de las Vacunas , Virus del Dengue/inmunologíaRESUMEN
BACKGROUND: The accurate etiological diagnosis of lower respiratory tract infections (LRTI) is essential for their effective clinical management. The extensive use of molecular methods during the COVID-19 pandemic has enabled massive data acquisition on viral lower respiratory tract infections. The current study aims to identify clinical features associated with eight viral agents among children presenting severe LRTI. METHODS: retrospective cohort study of data from the Brazilian Influenza Epidemiological Surveillance Information System. Patients under 20 years-old who had severe LRTI with etiological confirmation through RT-PCR between 2020 and 2022 were included. Binary logistic regressions were used to examine associations between pathogens and symptoms. RESULTS: 60,657 cases were assessed. The main viral agents detected were Sars-CoV-2 (COV2) (41.2%), Respiratory Syncytial Virus (29.1%), Human Rhinovirus (HRV) (12.1%), and Influenza (FLU) (5.5%). A general mortality rate of 4.3% was observed. The multivariate analysis evidenced that COV2 less likely presented with cough (OR: 0.34; 95%CI: 0.32-0.36), respiratory discomfort (Adjusted Odds Ratio (aOR): 0.61; 95%Confidence Interval (CI): 0.59-0.64), and desaturation (aOR: 0.71; 95%CI: 0.69-0.75). RSV strongly associated with cough (aOR: 2.59; 95%CI: 2.45-2.75) and respiratory discomfort (aOR: 1.54; 95%CI: 1.46-1.62), whereas FLU was linked to fever (aOR: 2.27; 95%CI: 2.06-2.50) and sore throat (aOR: 1.48; 95%CI: 1.34-1.64). CONCLUSIONS: The viral agents responsible for severe LRTI have distinct associations with clinical features in children.
Asunto(s)
Gripe Humana , Infecciones por Virus Sincitial Respiratorio , Virus Sincitial Respiratorio Humano , Infecciones del Sistema Respiratorio , Niño , Humanos , Lactante , Adulto Joven , Adulto , Gripe Humana/epidemiología , Estudios Retrospectivos , Brasil/epidemiología , Pandemias , Infecciones del Sistema Respiratorio/epidemiología , Tos , Infecciones por Virus Sincitial Respiratorio/epidemiologíaRESUMEN
Abstract The publication of medical articles has become increasingly complex, linked to multiple factors. It poses difficult problems for both authors and journals themselves. This Editorial addresses current and controversial issues: peer review, preprints as a new way of disseminating knowledge, the growing number of publications without peer review and its variants, and the risks of predatory publications. The article proposes future guidelines as an editorial policy of MEDICINA. The controversy continues, and surely the passage of time will place our proposal in a changing scientific world like knowledge itself.
RESUMEN
Introduction: The COVID-19 pandemic resulted in tremendous physical and psychological pressure on healthcare professionals, especially on those working in intensive care units (ICUs) and Emergency Departments (EDs). The present study intended to characterize the profile of these professionals which is associated with burnout and determine the potential predictors of such condition. Methods: A Prospective cohort study was carried out in a tertiary hospital between March 2020 and March 2021, in Salvador, Brazil. A standardized and validated version of the Oldenburg Burnout inventory (OLBI) was applied to assess risk of burnout together with data forms designed to collect information on sociodemographic characteristics and religious beliefs. ICU and ED healthcare professionals were evaluated during off-hours at two distinct periods of the COVID-19 pandemic, in 2020 and in 2021. Differences in the results obtained from each study participant between the timepoints were compared. A binary logistic regression analysis was performed to identify the predictors of burnout development independent of other confounding factors. Results: Seventy-seven healthcare professionals with a median age of 33 (interquartile range [IQR]: 31-37.5) years and predominantly female (72.7%; n = 56) were enrolled. There were 62 professionals at risk of developing burnout through the OLBI. Those had a median age of 33 (IQR: 31-37) and female predominance (71%, n = 44). Disengagement and burnout were the only features which frequencies significantly changed over time, with increasing detection at the latest timepoint. Alcohol consumption was found to be an important risk factor for burnout development [adjusted odds ratio (aOR): 10.8 (95% CI: 1.8-64.2)]. Importantly, working in the ICU [aOR: 0.04 (95%CI: 0.01-0.32)] and the habit of praying daily [aOR: 0.07 (95%CI: 0.01-0.41)] were characteristics linked to reduced odds of burnout. Discussion: Disengagement substantially increased during the COVID-19 pandemic in healthcare professionals. Alcohol consumption favors the onset of burnout whereas habit of praying daily and working in the ICU are protective against such outcome. Institutional policies aimed at minimizing etilism may positively impact mental health of these professionals.
RESUMEN
The publication of medical articles has become increasingly complex, linked to multiple factors. It poses difficult problems for both authors and journals themselves. This Editorial addresses current and controversial issues: peer review, preprints as a new way of disseminating knowledge, the growing number of publications without peer review and its variants, and the risks of predatory publications. The article proposes future guidelines as an editorial policy of MEDICINA. The controversy continues, and surely the passage of time will place our proposal in a changing scientific world like knowledge itself.
Asunto(s)
Medicina , Publicaciones Periódicas como Asunto , Humanos , Edición , Revisión por ParesRESUMEN
An analysis of explosive cyclone cases was produced by comparing the reanalysis of MERRA-2 (high spatial resolution) and NCEP2 (low spatial resolution) to South Atlantic in the 2014-2015 period. A total of 51 cases were found, of which 49 were detected by the first reanalysis and 33 by the second (2 cases identified by NCEP2 were not identified by MERRA-2). Spring was the dominant season in the formation of the cases in both reanalyses. It was observed that most systems are formed preferentially eastward of a preexisting trough at higher levels, while others are formed under an almost zonal upper airstream. This difference is more evident in the NCEP2. It was also diagnosed that the MERRA-2 shows more clearly the diffluence in the 250 hPa flow. The analysis of the composite fields revealed a negative horizontal tilt of the trough in 500 hPa, influenced by intense convection as the system develops. Besides, it pointed to a more pronounced jet stream in intense explosive cyclones and more prominent diffluence in non-intense cases. Since the NCEP2 reanalysis detected fewer cases (and only 2 intense) than MERRA-2, it was considered that the former is less suited to the analysis of this type of event.
Asunto(s)
Tormentas Ciclónicas , Estaciones del AñoRESUMEN
La foliculitis pseudolinfomatosa, descripta por McNutt en 1986, es una afección de etiología desconocida y poco frecuente, que simula un linfoma cutáneo tanto por su clínica como por su histología. Se presenta como una lesión nodular solitaria, eritematosa, de 0,5 hasta 3cm, de crecimiento rápido, sobre todo en la cara, en personas de 40 a 60 años, con una histopatología caracterizada por un infiltrado linfocitario B yT perifocular, y células dendríticas positivas en la inmunohistoquímica para S100yCD1a. Su curso es benigno, muchas veces autolimitado. Se expone el caso de una paciente con una particular forma clínica de pseudolinforma.
Pseudolymphomatous folliculitis, described by McNutt in 1986, is a non-frequent entity of unknown etiology that simulates a cutaneous lymphoma, both clinically and histologically. It shows as a solitary erythematous nodular lesion of 0.5 to 3 cm, with a rapid growth, mainly on the face, in people aged 40 to 60 years, and histopathology characterized by a perifollicular B and T lymphocytic infiltrate, and positive dendritic cells for immunohistochemistry S100 and CD1a. Its course is benign, often self-limited. The case of a patient with a particular clinical form of pseudolymphoma is presented.
Asunto(s)
Humanos , Femenino , Persona de Mediana Edad , Neoplasias Cutáneas , Seudolinfoma/diagnóstico , Foliculitis/diagnóstico , Triamcinolona Acetonida/administración & dosificación , Nariz/lesiones , Nariz/patología , Procedimientos Quírurgicos NasalesAsunto(s)
Humanos , Animales , Masculino , Femenino , Adolescente , Adulto , Persona de Mediana Edad , Anciano , Adulto Joven , Neumonía Viral/terapia , COVID-19/terapia , Sueros Inmunes/inmunología , Argentina , Ensayos Clínicos Controlados Aleatorios como Asunto , Inmunización Pasiva , SARS-CoV-2/inmunología , Caballos , Anticuerpos Antivirales/inmunología , Anticuerpos Antivirales/químicaRESUMEN
COVID-19 has had a rapid dissemination. Departing from China, the virus has traveled all around the world. With the use of accurate mathematical models, the global spread of the disease was anticipated. Some additional information to these predictive models could be provided by the comparison of freely available maps depicting commercial air travel routes and disease spread. This analysis informs on what seems to be a direct relationship between the initially unequal worldwide distribution of the disease and the density of the commercial air traffic. This comparison may also help to identify international distributional hubs of the disease out of China. The observation of this easily accessible information may contribute to the understanding of COVID-19 spill over and help health control policies to better focus on the spread of this and other aggressively spreading respiratory infectious diseases.
La novel enfermedad COVID-19 ha tenido una rápida diseminación. Desde China, el virus viajó por todo el mundo. El potencial de la propagación global de COVID-19 fue anticipado y calculado mediante el uso de modelos matemáticos precisos. A estos modelos predictores se puede agregar información obtenida mediante la comparación de mapas gratuitos que representan la propagación internacional de la enfermedad y la densidad de las rutas aerocomerciales. Este análisis proporciona información de lo que parece ser una relación directa entre la distribución mundial inicial desigual de la enfermedad y la densidad del flujo aerocomercial. Esta comparación también puede estar sugiriendo la presencia de centros internacionales de distribución secundaria fuera de China. Con esta información de rápido acceso se puede contribuir a la mejor comprensión del derrame internacional de COVID-19 y orientar los esfuerzos de las políticas de salud para el control de esta y otras enfermedades infecciosas respiratorias agresivas.